Cereno Scientific enters collaboration with University of Michigan9 June, 2020
Cereno Scientific today announced that the company enters a collaboration agreement with the University of Michigan in Ann Arbor, USA. On behalf of Cereno Scientific, Dr. Michael Holinstat, who is active at the University, is to initiate preclinical studies with compounds from Cereno’s HDACi development program. The studies will begin in June and investigate anti-thrombotic properties using in vitro and in vivo model systems.
“We welcome the collaboration with the University of Michigan and Mike Holinstat and are pleased that we are now further strengthening our preclinical expertise and capabilities,” said Sten R. Sörensen, Chief Executive Officer of Cereno Scientific.
Dr. Michael Holinstat received his Ph.D. in pharmacology from the University of Illinois at Chicago and completed postdoctoral training at Vanderbilt University in Nashville. His research interests include areas such as thrombosis, pharmacology and hematology. Dr. Holinstat is an Associate Professor in Pharmacology and lead the translational programs in drug development in Hemostasis and Thrombosis in the Department of Pharmacology at the University of Michigan. Dr. Holinstat has built a “state of the art” laboratory to investigate the effects of different pharmacological principles on platelets and coagulation both in vitro and in vivo.
In addition to the collaboration agreement, Cereno Scientific already has ties with the University of Michigan through the chairman of the company’s Scientific Advisory Board, Dr. Bertram Pitt, Professor Emeritus of Medicine at the University of Michigan School of Medicine.
About Cereno Scientific AB
Cereno Scientific is developing a pipeline of preventive therapeutics to treat cardiovascular and rare diseases by epigenetic modulation through histone deacetylase inhibition (HDACi). The company’s lead program, CS1, is a phase II dual-acting antithrombotic drug aimed at venous thrombosis and stroke prevention for atrial fibrillation. Cereno Scientific also evaluates the potential of epigenetic modulation for rare diseases related to pulmonary fibrosis, thrombosis, inflammation and high blood pressure in the pulmonary circulation system. The FDA has granted ODD for the indication Pulmonary Arterial Hypertension (PAH) to the company’s lead compund CS1. Cereno Scientific also has a preclinical HDAC inhibitor development program. The company is located in AstraZeneca’s BioVenture Hub. Cereno Scientific’s B share has been listed on Spotlight Stock market since June 2016 with the ticker CRNO B, ISIN SE0008241558.